(function(doc, html, url) {
var widget = doc.createElement("div");
widget.innerHTML = html;
var script = doc.currentScript; // e = a.currentScript;
if (!script) {
var scripts = doc.scripts;
for (var i = 0; i < scripts.length; ++i) {
script = scripts[i];
if (script.src && script.src.indexOf(url) != -1) break;
}
}
script.parentElement.replaceChild(widget, script);
}(document, '
Crystallisation of a GLP-1 analogue peptide
What is it about?
In this work, we explore a new way to understand and potentially produce peptide-based medicines, focusing on GLP-1/GIP analogue peptides used to treat type 2 diabetes and obesity. We report the crystal structure of this type of peptide in its free (unbound) form. By growing crystals and analysing them at high resolution, we show how the peptide molecules arrange themselves into an ordered, spiral-like structure, and identify the key interactions that hold this structure together.
Why is it important?
GLP-1 and GIP analogue peptides are an important and rapidly growing class of medicines, but they are difficult and expensive to manufacture. Current purification methods are often slow and inefficient. By determining this crystal structure, we provide new insight into how these peptides behave and interact at the molecular level. This helps address a key gap in understanding, particularly for peptides in their unbound form. This knowledge is important because it can help guide the development of improved purification strategies (such as crystallisation) and support more efficient manufacturing of these medicines.